Allianz Asset Management’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $15.1M | Sell |
1,859,854
-464,288
| -20% | -$4.21M | 0.02% | 711 |
|
|
2025
Q4 | $15.6M | Buy |
2,324,142
+914,408
| +65% | +$6.89M | 0.02% | 700 |
|
|
2025
Q3 | $12.2M | Buy |
1,409,734
+872,987
| +163% | +$6.79M | 0.01% | 760 |
|
|
2025
Q2 | $3.38M | Buy |
+536,747
| New | +$3.55M | ﹤0.01% | 1281 |
|
|
2024
Q2 | – | Sell |
-1,469,633
| Closed | -$7.02M | – | 2216 |
|
|
2024
Q1 | $7.02M | Buy |
1,469,633
+834,941
| +132% | +$3.87M | 0.01% | 757 |
|
|
2023
Q4 | $3.05M | Buy |
634,692
+199,771
| +46% | +$1.22M | 0.01% | 1141 |
|
|
2023
Q3 | $3.15M | Buy |
434,921
+40,669
| +10% | +$325K | 0.01% | 1206 |
|
|
2023
Q2 | $2.93M | Buy |
+394,252
| New | +$3.1M | 0.01% | 1114 |
|
|
2022
Q3 | – | Sell |
-29,882
| Closed | -$1.54M | – | 2043 |
|
|
2022
Q2 | $1.54M | Sell |
29,882
-41,980
| -58% | -$2.17M | ﹤0.01% | 1518 |
|
|
2022
Q1 | $5.29M | Buy |
71,862
+50,708
| +240% | +$4.52M | ﹤0.01% | 1199 |
|
|
2021
Q4 | $3.06M | Sell |
21,154
-116,470
| -85% | -$20M | ﹤0.01% | 1435 |
|
|
2021
Q3 | $28.5M | Buy |
137,624
+88,058
| +178% | +$19.4M | 0.02% | 604 |
|
|
2021
Q2 | $10.5M | Sell |
49,566
-32,095
| -39% | -$5.88M | 0.01% | 840 |
|
|
2021
Q1 | $14.8M | Buy |
81,661
+57,617
| +240% | +$11.5M | 0.01% | 709 |
|
|
2020
Q4 | $2.68M | Buy |
24,044
+20,882
| +660% | +$2.22M | ﹤0.01% | 1235 |
|
|
2020
Q3 | $343K | Buy |
+3,162
| New | +$385K | ﹤0.01% | 1684 |
|
|
2019
Q2 | – | Sell |
-846
| Closed | -$9K | – | 2741 |
|
|
2019
Q1 | $9K | Buy |
846
+324
| +62% | +$10.2K | ﹤0.01% | 2650 |
|
|
2018
Q4 | $19K | Buy |
+522
| New | +$20.2K | ﹤0.01% | 2581 |
|
|
2018
Q3 | – | Sell |
-22,208
| Closed | -$595K | – | 2686 |
|
|
2018
Q2 | $595K | Buy |
22,208
+420
| +2% | +$14.2K | ﹤0.01% | 2351 |
|
|
2018
Q1 | $915K | Buy |
+21,788
| New | +$875K | ﹤0.01% | 2238 |
|
|
2016
Q3 | – | Sell |
-29,790
| Closed | -$4.33M | – | 2630 |
|
|
2016
Q2 | $4.33M | Buy |
29,790
+10,403
| +54% | +$1.19M | ﹤0.01% | 1573 |
|
|
2016
Q1 | $2M | Buy |
19,387
+241
| +1% | +$25.9K | ﹤0.01% | 1818 |
|
|
2015
Q4 | $3.2M | Sell |
19,146
-37
| -0.2% | -$5.69K | ﹤0.01% | 1519 |
|
|
2015
Q3 | $2.71M | Buy |
19,183
+37
| +0.2% | +$8.3K | ﹤0.01% | 1501 |
|
|
2015
Q2 | $4.26M | Sell |
19,146
-428
| -2% | -$75.2K | ﹤0.01% | 1435 |
|
|
2015
Q1 | $3.24M | Buy |
19,574
+8,412
| +75% | +$1.37M | ﹤0.01% | 1376 |
|
|
2014
Q4 | $1.32M | Buy |
+11,162
| New | +$1.17M | ﹤0.01% | 1725 |
|
Other funds holding NVAX
SCM
VPM
VCM
S
Allianz Asset Management's NVAX Position: Q1 2026 in Review
Allianz Asset Management reduced its Novavax (NVAX) stake by 20% in Q1 2026, selling an estimated $4.21M and leaving 1,859,854 shares worth $15.1M. The position accounts for 0.02% of the portfolio, ranked #711.
Allianz Asset Management first reported a position in NVAX in Q4 2014 and has held it in 27 quarters since. The position peaked at $28.5M in Q3 2021. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.
- Allianz Asset Management held 1,859,854 shares of Novavax worth $15.1M as of Q1 2026.
- Allianz Asset Management sold 464,288 Novavax shares in Q1 2026, an estimated $4.21M.
- Novavax made up 0.02% of Allianz Asset Management's portfolio in Q1 2026, its #711 holding.
- Allianz Asset Management first reported a position in Novavax in Q4 2014 and has held it in 27 quarters since.
- Allianz Asset Management's Novavax position peaked at $28.5M in Q3 2021.
- 258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.
Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.